Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy
Yingyao Chen, Hengjin Dong, Yan Wei, Yi Yang, Jian Ming, Hao Yu
Abstract
<b>Yingyao Chen and colleagues</b> examine what can be learnt from China’s approach to funding expensive high technology medicines with uncertain long term benefit
Topics & Concepts
ReimbursementChinaCancer immunotherapyHealth technologyMedicineImmunotherapyHealth insuranceCancerData scienceComputer scienceHealth careInternal medicinePolitical scienceEconomic growthEconomicsLawBiosimilars and Bioanalytical MethodsHealth Systems, Economic Evaluations, Quality of LifeCancer Immunotherapy and Biomarkers